The FDA Roundtable Part I: The Regulators' View of Drug Development
This article was originally published in RPM Report
Executive Summary
Three top FDA officials sat down with The RPM Report at their White Oak campus to discuss the top drug regulatory issues. On the table for discussion: drug safety, comparative effectiveness and the future of drug development.